Post-Hoc Live: Jeremy Levin on biotech’s existential momentnews2026-05-26T17:39:25+00:00May 26th, 2026|Endpoints News|
GOP lawmaker asks Trump administration to curb China biotech dealsnews2026-05-22T17:50:05+00:00May 22nd, 2026|Endpoints News|
The next big pharma company will come from Chinanews2026-05-20T17:44:24+00:00May 20th, 2026|Endpoints News|
Bristol Myers joins Hengrui party in 13-asset deal worth up to $15.2Bnews2026-05-12T09:06:30+00:00May 12th, 2026|Endpoints News|
American Factories Lag in Adopting A.I. This Drugmaker Is an Exception.news2026-05-06T16:14:32+00:00May 6th, 2026|The New York Times|
American Factories Lag in Adopting A.I. This Drugmaker Is an Exception.news2026-05-06T16:14:32+00:00May 6th, 2026|The New York Times|
GSK goes to China for $1B siRNA deal in Arrowhead’s obesity lanenews2026-05-06T13:39:55+00:00May 6th, 2026|Endpoints News|
Biotech has a new startup model: Small team, big check and Chinese assetsnews2026-05-04T14:30:39+00:00May 4th, 2026|Endpoints News|
Windward Bio gets $165M to take China-derived drug into Phase 3 asthma trialnews2026-05-04T13:03:57+00:00May 4th, 2026|Endpoints News|
UCB bets $2 billion on Candid’s T cell engager ambitionsnews2026-05-04T01:54:30+00:00May 4th, 2026|Endpoints News|
